期刊文献+

氟伐他汀对系统性硬皮病成纤维细胞增殖及胶原分泌的影响 被引量:2

Effect of fluvastatin on the proliferation of fibroblasts and collagen secretion in systemic sclerosis
下载PDF
导出
摘要 目的:确定氟伐他汀对系统性硬皮病(systemic scleroderma,SS)皮肤成纤维细胞(fibroblasts,Fb)增殖及胶原分泌的影响。方法:原代培养SS患者皮肤Fb 72 h,四甲基偶氮唑盐(MTT)比色法检测不同浓度的氟伐他汀对细胞的存活力,并绘制不同浓度氟伐他汀作用下Fb的生长曲线;观察不同浓度的氟伐他汀对Fb胶原分泌的影响。结果:与空白对照组相比,各浓度的氟伐他汀均明显抑制患者皮肤Fb的增殖,使细胞的生长速度减慢,显著减少Fb培养液中可溶性胶原的含量,差异有显著性(P<0.05),且随着药物浓度的增高而增强,具有明显的浓度依赖性。结论:氟伐他汀对SS皮肤Fb的增殖及胶原的分泌均有显著抑制作用,为其治疗硬皮病提供了理论基础。 Objective: To determine the effect of fluvastatin on the proliferation of human skin fibroblasts and collagen secretion in systemic scleroderma (SS). Methods: Human skin fibroblasts were cuhm-ed. The potential of cell proliferation at different concentrations of fluvastatin was detected by the tetrazohum dye colorimetric test ( MTT Test). The growth curve of fibroblasts was drawn with MTT method. The collagen was detected by bio - chemical method. Results: Fluvastatin inhibited the proliferation of the cultured dermal fibroblasts of SS and reduced the syn- thesis of collagen in a dose - dependent manner. The difference was significant compared with controls ( P 〈 0.05). Conclusion: Fluvastatin can both inhibit the proliferation of skin fibroblasts and reduce the collagen secretion of dermal fibroblasts, which forms the base in the treatment of systemic scleroderma.
出处 《中国麻风皮肤病杂志》 2009年第9期645-647,共3页 China Journal of Leprosy and Skin Diseases
关键词 系统性硬皮病 氟伐他汀 成纤维细胞 systelnic sclerosis fluvastatin fibroblasts
  • 相关文献

参考文献6

二级参考文献56

  • 1[1]Sheppard MN,Harrison NK.New perspectives on basic mechanisms in lung disease.1. Lung injury,inflammatory mediators,and fibroblast activation in fibrosing alveolitis[J].Thorax,1992,47(12):1064-1074.
  • 2[2]Negre-Aminou P,van-Vliet AK,van-Erck M,et al.Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types [J].Biochim Biophys Acta,1997,1345(3):259-268.
  • 3[4]Carlberg M,Hjertman M,Wejde J,et al.Mevalonate is essential for growth activation of human fibroblasts:evidence for a critical role of protein glycosylation in the prereplicative period[J].Exp Cell Res,1994,212(2):359-366.
  • 4[5]Hancock JF,Magee AI,Childs JE,et al. All ras proteins are polyisoprenylated but only some are palmitoylated[J].Cell,1989,57(7):1167-1177.
  • 5[6]Bellosta S,Ferri N,Arnaboldi L,et al.Pleiotropic effects of statins in atherosclerosis and diabetes[J].Diabetes Care,2000,23(Suppl 2):B72-B78.
  • 6[7]Yoshimura A,Inui K,Nemoto T,et al. Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis[J].J Am Soc Nephrol,1998,9(11):2027-2039.
  • 7[8]Tan A,Levrey H,Dahm C,et al.Lovastatin induces fibroblast apoptosis in vitro and in vivo.A possible therapy for fibroproliferative disorders [J].Am J Respir Crit Care Med, 1999,159(1):220-227.
  • 8[1]Conrad CH,Brooks WW,Hayes JA,et al.Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat[J].Circulation,1995,91(1):161-8
  • 9[2]Querejeta R,López B,Gonzá1ez A,et al.Increased collagen type Ⅰ synthesis in patients with heart failure of hypertensive origin:relation to myocardial fibrosis[J].Circulation,2004,110:1263-8.
  • 10[3]LIPID Study Group.Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations:the LIPID trial follow-up[J].Lancet,2002,359(9315):1379-87.

共引文献25

同被引文献29

  • 1崔盘根,李晶冰,张彩萍,王淼淼,张传福,蒋明军,林麟.阿维A联合血管扩张剂治疗6例系统性硬皮病疗效观察[J].临床皮肤科杂志,2007,36(2):113-114. 被引量:6
  • 2Clements PJ,Furst DE,Wong WK,et al.High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis:analysis of a two-year,double-blind,randomized,controlled clinical trial[J].Arthritis Rheum,1999,42(6):1194-1203.
  • 3Derk CT,Huaman G,Jimenez SA.A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset[J].Br J Dermatol,2008,158(5):1063-1068.
  • 4Giordano N,Papakostas P,Lucani B,et al.Serum relaxin in systemic sclerosis[J].J Rheumatol,2005,32(11):2164-2166.
  • 5Seibold JR,Korn JH,Simms R,et al.Recombinant human relaxin in the treatment of scleroderma.A randomized,double-blind,placebo controlled trial[J].Ann Intern Med,2000,132(11):879-971.
  • 6Khanna D,Clements PJ,Furst DE.Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement:a randomized,double-blind,placebo-controlled trial[J].Arthritis Rheum,2009,60(4):1102-1111.
  • 7Krishna Sumanth M,Sharma VK,Khaitan BK,et al.Evaluation of oral methotrexate in the treatment of systemic sclerosis.Int J Dermatol 2007,46(2):218-223.
  • 8Miniati I,Matucci Cerinic M.Pulmonary fibrosis in systemic sclerosis:is treatment with cyclophosphamide more effective than placebo[J].Nat Clin Pract Rheumatol,2007,3(7):372-373.
  • 9Beretta L,Caronni M,Raimondi M,et al.Oral cyclophosphamide improves Pulmonary function in scleroderma patients with fibrosing alveolitis:experience in one centre[J].Clin Rheumatol,2007,26(2)168-172.
  • 10Nadashkevich O,Davis P,Fritzler M,et al.A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis[J].Clin Rheumatol,2006,25(2):205-212.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部